Under a tenth of patients that would benefit from GLP-1 drugs like Wegovy are able to get them, caution the global health agency as it publishes its initial guidance on the drugs.
With in excess of 1,000,000,000 individuals worldwide currently classified as obese, it is advocating for broader and more equitable access to these injectable treatments.
Based on forecasts, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken.
"The latest guidance recognises that obesity is a chronic disease that can be treated with comprehensive and ongoing support," stated the agency's head Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant barriers to broad access to the injections that can help people shift substantial body mass, notes the body.
Skinny Jab Supply Crisis
Even in the present most favorable scenario, the manufacturing of these medications could only cover around 100 million people – less than 10% of eligible patients, according to the health organization.
The recommendation calls on governments and firms to increase availability, through approaches such as licensing agreements.
Exclusive production rights on the active ingredient – the main ingredient of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
The Way Weight-Loss Injections Work
GLP-1 drugs imitate a body's own hormone to reduce digestion speed, suppress the appetite and boost the sense of being full so individuals reduce food intake.
Patients commonly begin shedding pounds in the initial weeks of commencing the regular doses.
Studies points to users may see weight return a year later of stopping the drug, when their typical appetite resume.
Being overweight or obese raises your risk for experiencing diseases, such as diabetes, heart disease, brain attack, and certain cancers.
Obesity concerns individuals in every country and was responsible for over three and a half million fatalities worldwide in 2024, as per the health agency.
